Last reviewed · How we verify
LEO 43204 Gel, 0.037%
At a glance
| Generic name | LEO 43204 Gel, 0.037% |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp (PHASE3)
- Biological Effects of LEO 43204 in Actinic Keratosis (PHASE1)
- Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 43204 Gel, 0.037% CI brief — competitive landscape report
- LEO 43204 Gel, 0.037% updates RSS · CI watch RSS
- LEO Pharma portfolio CI